证券日报网讯汉森制药9月5日在互动平台回答投资者提问时表示，截至2025年8月29日，公司含信用账 户合并股东名册的股东总数为：23580户。 （文章来源：证券日报） ...

证券日报网讯汉森制药（002412）9月3日在互动平台回答投资者提问时表示，截至2025年8月29日，公 司含信用账户合并股东名册的股东总数为23580户。 ...

Group 1 - The company, Hansen Pharmaceutical, has confirmed that its product, Si Mo Tang Oral Liquid, has been selected for procurement in multiple projects, including the Beijing-Tianjin-Hebei "3+N" alliance and the fourth batch of centralized procurement in Fujian [2] - The product has also received selected qualification in the fifth round of drug centralized procurement in Jiangsu Province and has limited procurement qualifications in the Guangdong alliance for Jin Lianhua and other traditional Chinese medicine projects [2]

Group 1 - The core viewpoint of the news is that Hansen Pharmaceutical experienced a decline in stock price and significant financing activity on August 29, with a net financing outflow of 475.93 million yuan [1] - On August 29, Hansen Pharmaceutical's financing buy-in amounted to 9.87 million yuan, while the financing repayment was 14.63 million yuan, resulting in a total financing balance of 142 million yuan, which represents 4.19% of its market capitalization [1] - The company has a high financing balance, exceeding the 50th percentile level over the past year, indicating a relatively elevated financing position [1] Group 2 - Hansen Pharmaceutical, established on January 21, 1998, and listed on May 25, 2010, specializes in the research, production, and sales of traditional Chinese medicine, chemical drugs, and medical preparations [2] - The main revenue sources for Hansen Pharmaceutical include Si Mo Tang oral liquid (54.81%), Tian Ma Xing Nao capsules (23.38%), and other products, with a total revenue of 5.09 billion yuan for the first half of 2025, reflecting a year-on-year growth of 5.91% [2] - The net profit attributable to the parent company for the same period was 68.54 million yuan, showing a year-on-year decrease of 31.80% [2] Group 3 - Since its A-share listing, Hansen Pharmaceutical has distributed a total of 485 million yuan in dividends, with 151 million yuan distributed over the past three years [3]

Core Viewpoint - Hansen Pharmaceutical experienced a decline of 4.18% in stock price on August 27, with a trading volume of 131 million yuan, indicating potential market volatility and investor sentiment concerns [1] Financing Summary - On August 27, Hansen Pharmaceutical had a financing buy-in amount of 15.20 million yuan and a financing repayment of 15.99 million yuan, resulting in a net financing buy of -0.797 million yuan [1] - The total financing and securities balance for Hansen Pharmaceutical as of August 27 is 144 million yuan, which accounts for 4.30% of its circulating market value, indicating a relatively high financing level compared to the past year [1] - The company had no short-selling activity on August 27, with a short-selling balance of 0.00 shares, suggesting a lack of bearish sentiment among investors [1] Company Overview - Hansen Pharmaceutical, established on January 21, 1998, and listed on May 25, 2010, is located in Yiyang City, Hunan Province, and specializes in the research, production, and sales of traditional Chinese medicine, chemical drugs, and medical preparations [2] - The company's main revenue sources include: Si Mo Tang Oral Liquid (54.81%), Tian Ma Xing Nao Capsules (23.38%), and other products, with the top three products contributing significantly to total revenue [2] - As of July 31, the number of shareholders increased by 1.15% to 24,400, while the average circulating shares per person decreased by 1.13% to 20,388 shares [2] Financial Performance - For the first half of 2025, Hansen Pharmaceutical reported a revenue of 509 million yuan, reflecting a year-on-year growth of 5.91%, while the net profit attributable to shareholders decreased by 31.80% to 68.54 million yuan [2] - The company has distributed a total of 485 million yuan in dividends since its A-share listing, with 151 million yuan distributed over the past three years [3]

据证券之星公开数据整理，近期汉森制药（002412）发布2025年中报。根据财报显示，汉森制药增收不 增利。截至本报告期末，公司营业总收入5.09亿元，同比上升5.91%，归母净利润6853.84万元，同比下 降31.8%。按单季度数据看，第二季度营业总收入2.4亿元，同比上升5.81%，第二季度归母净利润 5728.13万元，同比上升35.64%。 本次财报公布的各项数据指标表现一般。其中，毛利率76.78%，同比增2.91%，净利率13.47%，同比减 35.61%，销售费用、管理费用、财务费用总计2.27亿元，三费占营收比44.62%，同比减6.5%，每股净资 产4.48元，同比增8.57%，每股经营性现金流0.22元，同比增155.49%，每股收益0.14元，同比减31.8% | 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | 4.8亿 | 5.09亿 | 5.91% | | 归母净利润(元) | 1亿 | 6853.84万 | -31.80% | | 扣非净利润(元) | 9485.71万 | 0 6476 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002412 证券简称：汉森制药 公告编号：2025-018 湖南汉森制药股份有限公司 关于控股股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或者重大 遗漏。 湖南汉森制药股份有限公司（以下简称"公司""本公司"）于近日接到控股股东海南汉森控股（有限合 伙）（以下简称"海南汉森"）通知，获悉海南汉森所持有本公司的部分股份已办理了解除质押手续，具 体事项如下： 一、本次解除质押的基本情况 ■ 截至公告披露日，上述股东所持股份质押情况如下： ■ 三、其他情况说明 截至公告披露日，公司控股股东所质押的股份不存在平仓风险，不会导致公司实际控制权变更，不会对 公司生产经营、公司治理等产生影响。公司将持续关注控股股东股份质押的后续进展情况，并按规定及 时履行信息披露义务。 四、备查文件 （一）股份质押登记证明 二、控股股东股份累计质押的情况 （二）中国证券登记结算有限责任公司证券质押及司法冻结明细表 湖南汉森制药股份有限公司 董事会 2025年8月27日 ...

Core Points - The company has received notification from its controlling shareholder, Hainan Hansen Holdings, regarding the release of part of its pledged shares [1] - A total of 13,000,000 shares, accounting for 6.13% of the total share capital, were released from pledge on August 25, 2025 [1] - As of the announcement date, the controlling shareholder has pledged a total of 212,006,189 shares, which is 42.13% of its holdings [1] Summary by Sections 1. Release of Pledged Shares - Hainan Hansen released 13,000,000 shares from pledge, which represents 6.13% of its total holdings and 2.58% of the company's total share capital [1] - The shares were originally pledged on March 29, 2023, and the release date was August 25, 2025 [1] 2. Pledged Shares Situation - The total number of pledged shares by the controlling shareholder is 212,006,189, which constitutes 42.13% of its holdings [1] - The pledged shares represent 34,500,000 shares, accounting for 16.27% of the total share capital [1] 3. Other Situations - There is no risk of forced liquidation of the pledged shares, and it will not lead to a change in the company's actual control [1] - The company will continue to monitor the situation regarding the pledged shares and fulfill its information disclosure obligations as required [1]

证券日报网讯 8月26日晚间，汉森制药发布公告称，控股股东海南汉森控股（有限合伙）在长沙银行股 份有限公司华龙支行办理了股票解除质押业务，解除质押股份数量为1300万股，占其所持股份比例 6.13%，占公司总股本比例2.58%。 （编辑 楚丽君） ...

每经AI快讯，8月26日，汉森制药公告，公司控股股东海南汉森于2025年8月25日解除了1300万股的质 押，占其所持股份的6.13%，占公司总股本的2.58%。截至公告披露日，海南汉森累计质押股份数量为 3450万股，占其所持股份的16.27%，占公司总股本的6.86%。 ...